Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Stats
Jan 30, 202661.8
AI Score
BUY1.16
Volume Ratio
Feb 09, 2026
Next Earnings
15
+ve Days (30d)
15
-ve Days (30d)
INCY Stock Summary
Last updated Jan 30, 2026
INCY is currently trading at $100.07, positioned above its 200-day moving average of $83.34, indicating a long-term uptrend. The stock has a 52-week range of $53.56 to $112.29.
Technical Analysis: The 50-day moving average stands at $101.84, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 44.275, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.134, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates INCY at 61.8/100 with a BUY recommendation.
INCY (Incyte Genomics Inc) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 44.275 |
| CMF (20) | 0.134 |
| ROC (10) | -4.913 |
| ADX (14) | 16.158 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.035 |
| AROONOSC (14) | -50.0 |
| WILLAMS %R (14) | -87.461 |
| MFI (14) | 39.572 |
INCY Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
INCY Price vs Max Options Open Interest
INCY Max Change In Options Open Interest
INCY Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INCY Daily Out of Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INCY Daily In the Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
INCY Most Active Options by Volume(near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Incyte Genomics Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
INCY Moving Averages Analysis
Incyte Genomics Inc has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jan 30, 2026
INCY (Incyte Genomics Inc) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 102.88 |
| 20 | 104.15 |
| 30 | 102.68 |
| 50 | 101.84 |
| 100 | 96.27 |
| 200 | 83.34 |
INCY Fundamental Analysis
| P/E (Forward) | 13.624 |
| P/E (Trailing) | 17.1492 |
| Market Cap ($) | 19.9 billion |
| Earnings/Share ($) | 5.9 |
| Net Proft Margin (%) | 0.247 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 6.855 |
| EPS Estimate Next Year ($) | 7.878 |
| WallStreet Target Price ($) | 102.3333 |
| Most Recent Quarter |